Macedonian Journal
of
Medical Sciences
|
||||
|
||||
About MJMS |
Our policies |
MJMS Online |
For contributors |
Services |
Editorial & publishing policies |
Online first |
Guidelines
[pdf] |
Transliteration |
Abstract [Full-Text PDF] [Macedonian Abstract] [OnlineFirst Full-Text PDF]
Macedonian Journal of Medical Sciences. 2009 Mar 15; 2(1):22-29. doi:10.3889/MJMS.1857-5773.2009.0037 Basic Science
Effects of
Rosiglitazone on Metabolic Parameters and Adiponectin Levels in Fructose-Fed
Rats 1Institute
of Preclinical and Clinical Pharmacology with Toxicology, Faculty of
Medicine, University “Ss Kiril and Metodij”, Skopje, Republic of Macedonia;
2Institute of Immunobiology and Human Genetics, Faculty of
Medicine, University “Ss Kiril and Metodij”, Skopje, Republic of Macedonia;
3Endocrinology and Metabolic Disorders Clinic, Faculty of
Medicine, University “Ss Kiril and Metodij”, Skopje, Republic of Macedonia
Aim. To investigate the effect of the peroxisome proliferators-activator receptor gamma agonist, rosiglitazone, on metabolic parameters and adiponectin levels in an animal model of the metabolic syndrome. Material and methods. Metabolic syndrome was induced in 32 male Wistar rats by adding a fructose in drinking water for 12 weeks. During the last 4 weeks, 16 rats were treated with rosiglitazone (5 mg/kg/day), while the remaining 16 did not receive any medication (fructose group). Another control group consumed standard rat chow and water for 12 weeks. Results. Chronic fructose administration induced a significant increase in systolic blood pressure (SBP), body weight, serum triglycerides (TG), free fatty acids (FFA), insulin, glucose AUC0-120 (during oral glucose tolerance test) and decreased serum high density lipoprotein (HDL) cholesterol and adiponectin concentrations compared with the control group. Treatment with rosiglitazone over the final 4 weeks reversed these effects and significantly reduced SBP, TG, FFA, insulin concentrations and glucose AUC0-120 compared with the fructose group. In addition, rosiglitazone increased serum levels of adiponectin twofold from 3.44 ± 0.46 to 7.03 ± 1.30 mg/ml.Conclusion. This study indicates that rosiglitazone treatment improves the components of the metabolic syndrome, which is accompanied with an increase in adiponectin concentrations.
Key words: Rosiglitazone; adiponectin; metabolic syndrome; fructose; insulin. |
Publication of the MJMS is supported by
the
Macedonian
Ministry of Education and
Sciences.
Publisher: Institute of Immunobiology and Human Genetics, Skopje, Republic of Macedonia. |
||
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics. | ||
MJMS
Print
(ISSN 1857-5749) is an international peer-reviewed, Open
Access journal published four times per year. MJMS Online (ISSN 1857-5773) offers free access to all articles at http://www.mjms.ukim.edu.mk/. |
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution License.